Insight Molecular Diagnostics Inc. — Director's Dealing 2016

Feb 18, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2016-02-16

Reporting Person: KINGSLEY ALFRED D (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-16	Option to Purchase Common Stock	$3.06	A	50000	Acquired	2026-02-15	Common Stock (50000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	296902	Direct
Common Stock, no par value	75345	Indirect
Common Stock, no par value	18767	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$2.20	2025-01-08	Common Stock (75000)	75000	Direct
Option to Purchase Common Stock	$1.34	2020-12-28	Common Stock (125000)	125000	Direct

Footnotes

F1: Will become exercisable in four equal installments at the end of each calendar quarter based upon continued service on the board of directors from the date of grant.

F2: One quarter of these options vested on January 8, 2016, and the balance shall vest in 36 monthly installments commencing on the first anniversary of the date of grant.

F3: 1/48th of the number of options vested and became exercisable at the end of each full month after the date of grant on December 29, 2010.